Paper Diagnostics Market
Paper Diagnostics Market By Product Type (Paper-based Lateral Flow Assays, Dipsticks, Paper Based Microfluidics), By End User (Hospitals & Clinics, Homecare Settings) & By Region - Global Insights to 2031
Analysis of Paper Diagnostics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Market Outlook for Paper Diagnostics
As per the latest industry analysis published by Fact.MR, global market for paper diagnostics is likely to be valued at US$ 7.2 Bn in 2021, and is slated to accelerate at a CAGR of 8.1% across the 2021 to 2031 forecast period, reflecting more than 2x increase. Paper-based lateral flow assays are projected to be most demanded, accumulating over 60% revenue until 2031.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Key Points Covered in Paper Diagnostics Industry Survey
- Market Estimates and Forecasts 2016 to 2031
- Key drivers and restraints shaping market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact on Paper Diagnostics Market and How to Navigate
- Recommendation and Key Winning Strategy
Sales Analysis of Paper Diagnostics 2016 to 2020 Vs Future Outlook 2021 to 2031
Historically, the global paper diagnostics market flourished at a robust rate of nearly 7% CAGR from 2016 to 2020. Rapid advancements in diagnostic approaches, including a shift towards low cost diagnosis, has been one of the key influencing factors impacting demand.
The COVID-19 pandemic further opened new avenues for the paper diagnostics industry expansion. With substantial limitations associated with mainstream diagnostic approaches (RT-PCR, ELISA and RT-LAMP), clinicians have been adopting paper diagnostics for understanding viral genome sequence and better understand its spread.
Soaring R&D investments and increasing government stimulus to the healthcare sector is expected to surge in the forecast period. The market worth is projected to reach US$ 15.7 Bn, following a CAGR of 8.1% during the 2021 to 2031 assessment period. Furthermore, growing cases of cancer and advanced healthcare infrastructure in North America will enhance paper diagnostics prospects in the upcoming decade.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Increasing Cases of Autoimmune Diseases Bolstering Growth
Rising cases of autoimmune diseases and cancers coupled with the growing awareness among solutions available for fast and prompt diagnosis have resulted in high demand for the early detection of these diseases. According to the recent report of National Institutes of Health (NIH) published in April, 2020, the prevalence of autoimmune diseases in the United States was 11.0% for 1988 to 1991 and it had been increasing steadily to reach at 11.5% during 1999 to 2004 and at 15.9% during 2011 to 2012.
Paper diagnostics provide promising solutions for early diagnosis of these diseases while emphasizing on the key aspects of the diagnosis procedure and outcomes such as affordability, sustainability, portability, disposability, and others. According to the National Health and Nutrition Examination Survey (NHANES) of NIH, the rate of auto-immune diseases is forecast to grow further in the United States in the coming years. The data indicates that demand for paper diagnostics will surge considerably in the coming years
Technological Advancements to Open More Opportunistic Doors?
Advances in printed electronics provide a fitting foundation for implementing augmented functionality, while maintaining the affordability and disposability of paper-based diagnostics. Introduction of the technologically advanced paper-based sensor, 3D wax printing methods have potential advantages over conventional technologies, correlated benefits such as user-friendliness disposable nature, and low cost of fabrication are the factors associating towards the growth of this industry.
Currently, paper-based sensors are focused on microfluidic delivery of solution to the detection site whereas more advanced designs involve complex 3-D geometries based on the same microfluidic principles. Moreover, increasing investments by government organizations in R&D pertaining to development of novel in vitro diagnostics tests and devices have been providing an upthrust to the market. For instance, European Diagnostic Manufacturers Association (EDMA), which focuses on development and overall growth of the in vitro diagnostic industry in Europe, invests approximately € 1 billion in R&D of in vitro diagnostics every year.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Analysis
How is Cancer Diagnostics Pushing Demand for Paper Diagnostics in the U.S?
The U.S is the epicentre for paper diagnostics in the world due to the burgeoning number of cancer cases and progressive healthcare infrastructure. According to the National Cancer Institute, the U.S. is likely to have 1,806,590 new cases of cancer in 2020 and nearly 606,520 people might succumb to the disease.
The demand for early and effective detection of cancer has therefore become a priority for the healthcare industry in North America. This in turn is boosting the demand for paper diagnostics in the region. According to Fact.MR, the country is expected to surge at over 8% CAGR.
The U.S has some of the world’s R&D facilities allowing it to offer some of the most cutting-edge items to the clients. For instance, a group of engineers from the Massachusetts Institute of Technology (MIT) have developed an inexpensive paper-based test which could improve cancer diagnosis rates based on urine samples by analysing biomarkers.
How is the Prevention of Infectious Diseases Outbreaks Driving Adoption in China?
According to fact.MR, China is likely to generate high prospects for the paper diagnostics industry, registering a CAGR of 6.6% during the forecast period.
High burden of chronic and infectious diseases, including diabetes, cancer, and COVID-19, is slated to significantly propel growth, as these chronic disorders can be diagnosed and monitored using paper diagnostic products.
According to the World Health Organization (WHO), 102,762 COVID-19 cases were recorded as of March 2021, with 4,851 deaths in China. The increasing burden of the COVID-19 pandemic will lead to a high requirement of tests, which will boost the paper diagnostics market in the country.
Category-wise Insights
Why Lateral Flow Assays are experiencing an Incline in the Industry?
Currently, lateral flow assays are the leading segment in terms of product type in the global market for paper diagnostics. This segment will likely account for over 60% revenue until 2031. Growth can be attributed to extensive usage rate as pregnancy tests.
Besides, mounting incidence of infectious diseases such as HIV, TB, and pneumonia is assessed to spur the growth of the segment during the forecast period. Lateral flow assay (LFA) has made a paradigm shift in the in vitro diagnosis field due to its rapid turnaround time, ease of operation and exceptional affordability. Currently used LFAs predominantly use antibodies.
How did COVID-19 Spur Paper Diagnostics across Hospitals & Clinics?
In terms of end-user, hospitals and clinics are the foremost utilizers of paper diagnostics. With the increase in awareness among doctors, other healthcare staff, and patients, the demand for paper diagnostics solutions is rising. Fact.MR expects the segment to experience a CAGR of 7% until 2031.
During the height of the coronavirus pandemic, documented limitations associated with rapid diagnostic approaches such as RT-PCR (real-time PCR), RT-LAMP and ELISA prompted high reliance on paper-based diagnostics, capable of testing viral genome sequence to reflect information on the spread and distribution of the pathogen, especially in wastewater.
Competitive Landscape
Prominent players are embracing innovative approaches such as ground-breaking marketing tactics, enhanced R&D investments, technological advancements and mergers.
- The Wyss Institute has developed paper-based synthetic gene networks as a next generation diagnostic technology for use in global healthcare crises and patient-care. This new type pf platform may also provide patients and consumers with simple-to-use texts for a variety of other health problems.
- In Sept 2017, U.S. ARKRAY, Inc. (ARKRAY) launched the ADAMS™ A1c HA-8180V System for haemoglobin A1c testing. The system obtained FDA 510(k) clearance as an aid in the monitoring and diagnosis of individuals with diabetes. This fully automated analyser utilizes gold standard HPLC technology.
Report Scope
| Attribute | Details |
|---|---|
| Market size value in 2020 | USD 7.2 Billion |
| Market forecast value in 2031 | USD 15.7 Billion |
| Growth Rate | CAGR of 8.1% (2021 to 2031) |
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Market Analysis | US$ Mn for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Covered | U.S., Canada, Germany, U.K., France, Spain, Italy, Russia, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Brazil, Mexico, Argentina, GCC, South Africa |
| Key Market Segments Covered | Product, End User, Region |
| Key Companies Profiled | Abcam Plc.; Acon Laboratories Inc.; Bio-Rad Laboratories Inc.; Siemens Healthineers; Chembio Diagnostic Systems Inc.; Arkray Inc.; Cytodiagnostics Inc. |
| Pricing | Available upon Request |
Key Segments Covered
-
By Product:
- Paper-based Lateral Flow Assays
- Paper-based Dipsticks
- Paper-based Micro Fluidics
-
By End User:
- Paper Diagnostics for Hospitals & Clinics
- Paper Diagnostics for Home Care Settings
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Market Context
- 5. Market Background
- 6. Global - Pricing Analysis
- 7. Global Value Analysis 2016 to 2020 and Forecast, 2021 to 2031
- 8. Global Analysis 2016 to 2020 and Forecast 2021 to 2031, By Product
- 8.1. Lateral Flow Assays
- 8.2. Dipsticks
- 8.3. Paper Based Microfluidics
- 9. Global Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
- 9.1. Hospitals & Clinics
- 9.2. Homecare Settings
- 10. Global Analysis 2016 to 2020 and Forecast 2021 to 2031, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Europe
- 10.4. East Asia
- 10.5. South Asia
- 10.6. Oceania
- 10.7. Middle East and Africa (MEA)
- 11. North America Analysis 2016 to 2020 and Forecast 2021 to 2031
- 12. Latin America Analysis 2016 to 2020 and Forecast 2021 to 2031
- 13. Europe Analysis 2016 to 2020 and Forecast 2021 to 2031
- 14. South Asia Analysis 2016 to 2020 and Forecast 2021 to 2031
- 15. East Asia Analysis 2016 to 2020 and Forecast 2021 to 2031
- 16. Oceania Analysis 2016 to 2020 and Forecast 2021 to 2031
- 17. Middle East and Africa Analysis 2016 to 2020 and Forecast 2021 to 2031
- 18. Key and Emerging Countries Analysis 2016 to 2020 and Forecast 2021 to 2031
- 19. Market Structure Analysis
- 20. Competition Analysis
- 20.1. Abcam PLC
- 20.2. Acon Laboratories
- 20.3. Bio-Rad Laboratories Inc.
- 20.4. Siemens Healthineers
- 20.5. Chembio Diagnostic Systems Inc.
- 20.6. Arkray Inc.
- 20.7. Cytodiagnostics Inc.
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Product
Table 02: Global Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By End User
Table 03: Global Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Region
Table 04: North America Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Country
Table 05: North America Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Product
Table 06: North America Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By End User
Table 07: Latin America Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Country
Table 08: Latin America Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Product
Table 09: Latin America Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By End User
Table 10: Europe Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Country
Table 11: Europe Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Product
Table 12: Europe Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By End User
Table 13: South Asia Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Country
Table 14: South Asia Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Product
Table 15: South Asia Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By End User
Table 16: East Asia Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Country
Table 17: East Asia Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Product
Table 18: East Asia Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By End User
Table 19: Oceania Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Country
Table 20: Oceania Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Product
Table 21: Oceania Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By End User
Table 22: MEA Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Country
Table 23: MEA Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Product
Table 24: MEA Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Value Analysis (US$ Mn), 2016 to 2020
Figure 02: Global Value Forecast (US$ Mn), 2021 to 2031
Figure 03: Global Absolute $ Opportunity, 2021 to 2031
Figure 04: Paper Diagnostics Pricing Analysis (US$) for Per Unit, By Region, 2020
Figure 05: Global Share Analysis (%), By Product, 2021 to 2031
Figure 06: Global Y-o-Y Analysis (%), By Product, 2021 to 2031
Figure 07: Global Attractiveness Analysis, By Product, 2021 to 2031
Figure 08: Global Share Analysis (%), By End User, 2021 to 2031
Figure 09: Global Y-o-Y Analysis (%), By End User, 2021 to 2031
Figure 10: Global Attractiveness Analysis, By End User, 2021 to 2031
Figure 11: Global Share Analysis (%), By Region, 2021 to 2031
Figure 12: Global Y-o-Y Analysis (%), By Region, 2021 to 2031
Figure 13: Global Attractiveness Analysis, By Region, 2021 to 2031
Figure 14: North America Value Share, By Product, 2021 (E)
Figure 15: North America Value Share, By End User, 2021 (E)
Figure 16: North America Value Share, By Country, 2021 (E)
Figure 17: North America Value Analysis (US$ Mn), 2016 to 2020
Figure 18: North America Value Forecast (US$ Mn), 2021 to 2031
Figure 19: North America Attractiveness Analysis, by Product, 2021 to 2031
Figure 20: North America Attractiveness Analysis by End User, 2021 to 2031
Figure 21: North America Attractiveness Analysis by Country, 2021 to 2031
Figure 22: Latin America Value Share, By Product, 2021 (E)
Figure 23: Latin America Value Share, By End User, 2021 (E)
Figure 24: Latin America Value Share, By Country, 2021 (E)
Figure 25: Latin America Value Analysis (US$ Mn), 2016 to 2020
Figure 26: Latin America Value Forecast (US$ Mn), 2021 to 2031
Figure 27: Latin America Attractiveness Analysis, By Product, 2021 to 2031
Figure 28: Latin America Attractiveness Analysis by End User, 2021 to 2031
Figure 29: Latin America Attractiveness Analysis by Country, 2021 to 2031
Figure 30: Europe Value Share, By Product, 2021 (E)
Figure 31: Europe Value Share, By End User, 2021 (E)
Figure 32: Europe Value Share, By Country, 2021 (E)
Figure 33: Europe Value Analysis (US$ Mn), 2016 to 2020
Figure 34: Europe Value Forecast (US$ Mn), 2021 to 2031
Figure 35: Europe Attractiveness Analysis, By Product, 2021 to 2031
Figure 36: Europe Attractiveness Analysis by End User, 2021 to 2031
Figure 37: Europe Attractiveness Analysis by Country, 2021 to 2031
Figure 38: South Asia Value Share, By Product, 2021 (E)
Figure 39: South Asia Value Share, By End User, 2021 (E)
Figure 40: South Asia Value Share, By Country, 2021 (E)
Figure 41: South Asia Value Analysis (US$ Mn), 2016 to 2020
Figure 42: South Asia Value Forecast (US$ Mn), 2021 to 2031
Figure 43: South Asia Attractiveness Analysis, By Product, 2021 to 2031
Figure 44: South Asia Attractiveness Analysis by End User, 2021 to 2031
Figure 45: South Asia Attractiveness Analysis by Country, 2021 to 2031
Figure 46: East Asia Value Share, By Product, 2021 (E)
Figure 47: East Asia Value Share, By End User, 2021 (E)
Figure 48: East Asia Value Share, By Country, 2021 (E)
Figure 49: East Asia Value Analysis (US$ Mn), 2016 to 2020
Figure 50: East Asia Value Forecast (US$ Mn), 2021 to 2031
Figure 51: East Asia Attractiveness Analysis, By Product, 2021 to 2031
Figure 52: East Asia Attractiveness Analysis by End User, 2021 to 2031
Figure 53: East Asia Attractiveness Analysis by Country, 2021 to 2031
Figure 54: Oceania Value Share, By Product, 2021 (E)
Figure 55: Oceania Value Share, By End User, 2021 (E)
Figure 56: Oceania Value Share, By Country, 2021 (E)
Figure 57: Oceania Value Analysis (US$ Mn), 2016 to 2020
Figure 58: Oceania Value Forecast (US$ Mn), 2021 to 2031
Figure 59: Oceania Attractiveness Analysis, By Product, 2021 to 2031
Figure 60: Oceania Attractiveness Analysis by End User, 2021 to 2031
Figure 61: Oceania Attractiveness Analysis by Country, 2021 to 2031
Figure 62: MEA Value Share, By Product, 2021 (E)
Figure 63: MEA Value Share, By End User, 2021 (E)
Figure 64: MEA Value Share, By Country, 2021 (E)
Figure 65: MEA Value Analysis (US$ Mn), 2016 to 2020
Figure 66: MEA Value Forecast (US$ Mn), 2021 to 2031
Figure 67: MEA Attractiveness Analysis, By Product, 2021 to 2031
Figure 68: MEA Attractiveness Analysis by End User, 2021 to 2031
Figure 69: MEA Attractiveness Analysis by Country, 2021 to 2031
Figure 70: U. S. Value Share, By Product, 2021 &2031
Figure 71: U. S. Value Share, By End User, 2021 &2031
Figure 72: Global Vs. U.S Growth Comparison
Figure 73: Canada Value Share, By Product, 2021 &2031
Figure 74: Canada Value Share, By End User, 2021 &2031
Figure 75: Global Vs. Canada Growth Comparison
Figure 76: Germany Value Share, By Product, 2021 &2031
Figure 77: Germany Value Share, By End User, 2021 &2031
Figure 78: Global Vs. Germany Growth Comparison
Figure 79: U. K. Value Share, By Product, 2021 &2031
Figure 80: U. K. Value Share, By End User, 2021 &2031
Figure 81: Global Vs. U. K. Growth Comparison
Figure 82: France Value Share, By Product, 2021 &2031
Figure 83: France Value Share, By End User, 2021 &2031
Figure 84: Global Vs. France Growth Comparison
Figure 85: Italy Value Share, By Product, 2021 &2031
Figure 86: Italy Value Share, By End User, 2021 &2031
Figure 87: Global Vs. Italy Growth Comparison
Figure 88: Spain Value Share, By Product, 2021 &2031
Figure 89: Spain Value Share, By End User, 2021 &2031
Figure 90: Global Vs. Spain Growth Comparison
Figure 91: Russia Value Share, By Product, 2021 &2031
Figure 92: Russia Value Share, By End User, 2021 &2031
Figure 93: Global Vs. Russia Growth Comparison
Figure 94: Japan Value Share, By Product, 2021 &2031
Figure 95: Japan Value Share, By End User, 2021 &2031
Figure 96: Global Vs. Japan Growth Comparison
Figure 97: China Value Share, By Product, 2021 &2031
Figure 98: China Value Share, By End User, 2021 &2031
Figure 99: Global Vs. China Growth Comparison
Figure 100: South Korea Share Analysis (%), By Product, 2021 &2031
Figure 101: South Korea Share Analysis (%), By End User, 2021 &2031
Figure 102: Global Vs South Korea Growth Comparison
Figure 103: India Share Analysis (%), By Product, 2021 &2031
Figure 104: India Share Analysis (%), By End User, 2021 &2031
Figure 105: Global Vs India Growth Comparison
Figure 106: Thailand Share Analysis (%), By Product, 2021 &2031
Figure 107: Thailand Share Analysis (%), By End User, 2021 &2031
Figure 108: Global Vs Thailand Growth Comparison
Figure 109: Malaysia Share Analysis (%), By Product, 2021 &2031
Figure 110: Malaysia Share Analysis (%), By End User, 2021 &2031
Figure 111: Global Vs Malaysia Growth Comparison
Figure 112: Indonesia Share Analysis (%), By Product, 2021 &2031
Figure 113: Indonesia Share Analysis (%), By End User, 2021 &2031
Figure 114: Global Vs Indonesia Growth Comparison
Figure 115: Australia Share Analysis (%), By Product, 2021 &2031
Figure 116: Australia Share Analysis (%), By End User, 2021 &2031
Figure 117: Global Vs Australia Growth Comparison
Figure 118: New Zealand Share Analysis (%), By Product, 2021 &2031
Figure 119: New Zealand Share Analysis (%), By End User, 2021 &2031
Figure 120: Global Vs New Zealand Growth Comparison
Figure 121: GCC Countries Share Analysis (%), By Product, 2021 &2031
Figure 122: GCC Countries Share Analysis (%), By End User, 2021 &2031
Figure 123: Global Vs GCC Countries Growth Comparison
Figure 124: Turkey Share Analysis (%), By Product, 2021 &2031
Figure 125: Turkey Share Analysis (%), By End User, 2021 &2031
Figure 126: Global Vs Turkey Growth Comparison
Figure 127: South Africa Share Analysis (%), By Product, 2021 &2031
Figure 128: South Africa Share Analysis (%), By End User, 2021 &2031
Figure 129: Global Vs South Africa Growth Comparison
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the paper diagnostics market worth?
As of 2021, paper diagnostics demand is estimated to reach nearly US$ 7.5 Bn
What was the last 5 years CAGR for the paper diagnostics industry?
From 2016 to 2020, paper diagnostics demand surged at a CAGR of 7%, as per Fact.MR
What are the future growth projections for paper diagnostics?
From 2021 to 2031, the market for paper diagnostics is projected to surge at a CAGR of 8.1%.
What is the anticipated valuation for the paper diagnostics industry by 2031?
According to Fact.MR, paper diagnostics value is likely to reach US$ 15.7 Bn by 2031
What factors drive the demand for paper diagnostics?
Growing incidences of autoimmune disorders as well as the foray to discover inexpensive alternatives are spurring paper diagnostics demand
What is the growth outlook for the Chinese paper diagnostics industry?
As per Fact.MR, demand for paper diagnostics in China is scheduled to expand at a CAGR of 6.6%
How opportunistic are prospects across the U.S?
The U.S is slated to experience a growth rate of over 8% across the 2021-2031 forecast period
Which key manufacturers operate in the paper diagnostics domain?
ARKRAY Inc., Acon Laboratories, Inc., Abbott, Bio-Rad Laboratories, Abcam Plc, Chembio Diagnostic Systems, Inc., FFEI, Navigene, Creative Diagnostics, Siemens Healthcare Gmbh., are some players operating in the paper diagnostics domain
Which is the fastest growing paper diagnostics product type?
Lateral Flow Assays are the most preferred, capturing 60% of the global revenue until 2031
Paper Diagnostics Market